Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen, and welcome to the Inovio Second Quarter 2026 Financial Assaults Conference Call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Wednesday, August 12, 2026. I would now like to turn the conference over to Jennie Willson, Director of Communications. Please go ahead. Thank you. Good afternoon, and thank you for joining the Adnopio Second Quarter 2026 Financial Results Conference Call. Joining me today are Dr. Jackie Shea, President and Chief Executive Officer, Dr. Mike Sumner, Chief Medical Officer, Steve Ege, Chief Commercial Officer, and Peter Kies, Chief Financial Officer. Today's call will review our corporate and financial information for the quarter ended June 30, 2026. as well as provide a general business update. Following prepared remarks, we will conduct a question and answer segment. During the call, we will be making forward-looking statements regarding future events and the future performance of the company. These statements relate to our business plans to develop Inovio's DNA medicines platform including Thank you for joining us today. Our belief regarding its competitive advantages relative to existing treatments, including Pepsimios, and the potential to become the preferred product and new standard of care for patients and their physicians, if approved. Our expectation to receive orphan drug market exclusivity for INO 3107, if approved, and the anticipated timing of label negotiations. The anticipated commercial launch of INO 3107, if approved. Our commercial launch infrastructure and preparations. are...